Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44


Aspirin plus tirofiban inhibit the thrombosis induced by Russell's viper venom.

Wu RC, Chou PT, Chen LK.

Thromb J. 2016 Oct 4;14(Suppl 1):38. eCollection 2016.


Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines.

Min SK, Kim YH, Joh JH, Kang JM, Park UJ, Kim HK, Chang JH, Park SJ, Kim JY, Bae JI, Choi SY, Kim CW, Park SI, Yim NY, Jeon YS, Yoon HK, Park KH.

Vasc Specialist Int. 2016 Sep;32(3):77-104. Epub 2016 Sep 30. Review.


Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism.

Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A.

J Thromb Thrombolysis. 2016 Aug;42(2):296-311.


Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.

Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK.

J Thromb Thrombolysis. 2016 Jan;41(1):165-86. doi: 10.1007/s11239-015-1315-2. Review.


Pharmacology of anticoagulants used in the treatment of venous thromboembolism.

Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A.

J Thromb Thrombolysis. 2016 Jan;41(1):15-31. doi: 10.1007/s11239-015-1314-3. Review. Erratum in: J Thromb Thrombolysis. 2016 Aug;42(2):296-311.


Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study.

Heit JA, Lahr BD, Ashrani AA, Petterson TM, Bailey KR.

Thromb Res. 2015 Aug;136(2):298-307. doi: 10.1016/j.thromres.2015.06.030. Epub 2015 Jun 24.


Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.

Prandoni P, Prins MH, Cohen AT, Müller K, Pap ÁF, Tewes MC, Lensing AW.

Acad Emerg Med. 2015 Feb;22(2):142-9. doi: 10.1111/acem.12585. Epub 2015 Feb 9.


New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.

Dobesh PP, Fanikos J.

Drugs. 2014 Nov;74(17):2015-32. doi: 10.1007/s40265-014-0301-x. Review.


Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism.

Said K.

Glob Cardiol Sci Pract. 2013 Dec 30;2013(4):416-20. doi: 10.5339/gcsp.2013.50. eCollection 2013.


Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.

Alquwaizani M, Buckley L, Adams C, Fanikos J.

Curr Emerg Hosp Med Rep. 2013 Apr 21;1(2):83-97. Print 2013 Jun.


Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.

Boroumand M, Goodarzynejad H.

J Tehran Heart Cent. 2010 Spring;5(2):57-68. Epub 2010 May 31.


In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.

Baldwin AD, Robinson KG, Militar JL, Derby CD, Kiick KL, Akins RE Jr.

J Biomed Mater Res A. 2012 Aug;100(8):2106-18. doi: 10.1002/jbm.a.34050. Epub 2012 May 21.


Evaluation of 2 weight-based protocols for administration of heparin.

Tsang D, Shalansky KF, Lum E.

Can J Hosp Pharm. 2009 Nov;62(6):448-56.


Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR.

Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Erratum in: Chest. 2012 Dec;142(6):1698-1704.


Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study.

Heit JA, Lahr BD, Petterson TM, Bailey KR, Ashrani AA, Melton LJ 3rd.

Blood. 2011 Nov 3;118(18):4992-9. doi: 10.1182/blood-2011-05-357343. Epub 2011 Sep 2.


Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment.

Rice KR, Brassell SA, McLeod DG.

Rev Urol. 2010 Spring;12(2-3):e111-24.


Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.

Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI.

Chest. 2010 Jun;137(6):1382-90. doi: 10.1378/chest.09-0959. Epub 2010 Jan 15.


The potential benefits of low-molecular-weight heparins in cancer patients.

Robert F.

J Hematol Oncol. 2010 Jan 14;3:3. doi: 10.1186/1756-8722-3-3. Review.

Supplemental Content

Support Center